Medikamenteninduzierter Lupus erythematodes tumidus unter Adalimumab-Therapie

Sohl, Sirius; Renner, Regina; Winter, Ursula; Bodendorf, Marc Oliver; Paasch, Uwe; Simon, J. C.; Treudler, Regina

doi:10.1007/s00105-008-1699-4

Cited by 17 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than half of patients (n=119) present clinically with isolated cutaneous involvement, some presenting with infrequent cutaneous features such as lupus tumidus or childblain lupus. (23)(24)(25) Involvement of internal organs was very infrequent and included lupus nephritis (n=10), neurolupus (n=4) and pulmonary involvement (n=1). Some studies have suggested as potential risk factors for an enhanced risk of developing induced lupus pre-existing positive immunological markers (ANA, anti-DNA antibodies) or a family history of SLE.…”

Section: Systemic Diseases A) Lupusmentioning

confidence: 99%

Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)

Pérez-de-Lis

Retamozo

Flores-Chávez

et al. 2017

Expert Opinion on Drug Safety

123

View full text Add to dashboard Cite

Biological drugs are therapies designed to target a specific molecule of the immune system that have been linked with the development of autoimmune diseases. Areas covered: The BIOGEAS Registry currently collects information about nearly 13,000 reported cases of autoimmune diseases developed in patients exposed to biologics, including more than 50 different systemic and organ-specific autoimmune disorders, of which psoriasis (n=6375), inflammatory bowel disease (n=845), demyelinating CNS disease (n=803), interstitial lung disease (n=519) and lupus (n=369) were the most frequently reported. The main biologics involved were anti-TNF agents in 9133 cases (adalimumab in 4154, infliximab in 3078 and etanercept in 1681), immune checkpoint inhibitors in 913 (ipilimumab in 524 and nivolumab in 225), B-cell targeted therapies in 741 (rituximab in 678), and growth factor inhibitors in 549 cases (bevacizumab in 544). Even though targeting a particular immune molecule may be associated with an excellent clinical response in most patients, an unexpected autoimmune disease may arise in around 8 out of 10,000 exposed patients. Expert opinion: Following the increased use of biologics, the number and diversity of induced autoimmune diseases is increasing exponentially. Management of these disorders will be an increasing clinical challenge in the daily practice in the next years.

show abstract

Section: Systemic Diseases A) Lupusmentioning

confidence: 99%

Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)

Pérez-de-Lis

Retamozo

Flores-Chávez

et al. 2017

Expert Opinion on Drug Safety

123

View full text Add to dashboard Cite

show abstract

“…Cigarette smoking has been associated with both TLE and DLE [25]. Multiple drugs have been described to induce TLE such as tumor necrosis factor-alpha (TNF-a) inhibitors, angiotensin-converting-2 enzyme inhibitors, and bortezomib [26][27][28][29]. TLE has rarely been reported in association with DLE and SLE [30,31].…”

Section: Etiopathogenesismentioning

confidence: 99%

Tumid Lupus Erythematosus (TLE): A Review of a Rare Variant of Chronic Cutaneous Lupus Erythematosus (cCLE) with Emphasis on Differential Diagnosis

Daruish,

Ambrogio,

Foti

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Tumid lupus erythematosus (TLE) has been the subject of heated debate regarding its correct nosographic classification. The definition of TLE has changed over time, varying according to the different studies performed. In this review, we address the initial definition of TLE, the changes that have taken place in the understanding of TLE, and its placement within the classification of cutaneous lupus erythematosus (CLE), with a focus on clinical, histopathological, immunophenotypical, and differential diagnosis aspects.

show abstract

“…Cigare e smoking has been associated with both TLE and DLE [25]. Multiple drugs have been described to induce TLE such as tumor necrosis factor-alpha (TNF-a) inhibitors, angiotensinconverting-2 enzyme inhibitors, and bortezomib [26][27][28][29]. TLE has rarely been reported in association with DLE and SLE [30,31].…”

Section: Etiopathogenesismentioning

confidence: 99%

Tumid Lupus Erythematosus (TLE): a review of a rare variant of chronic Cutaneous Lupus Erythematosus (cCLE) with emphasis on differential diagnosis

Daruish,

Ambrogio,

Foti

et al. 2024

Preprint

View full text Add to dashboard Cite

Tumid Lupus Erythematosus has been the subject of heated debate as to its correct nosographic classification. In particular, its definition has changed over time, depending on the different studies performed. In this review we address the initial definition of TLE, the changes that have taken place in the understanding and placement within the classification of Lupus Erythematosus (LE), and focus on clinical, histopathological, immunophenotypical and differential diagnosis aspects.

show abstract

Medikamenteninduzierter Lupus erythematodes tumidus unter Adalimumab-Therapie

Cited by 17 publications

References 12 publications

Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)

Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)

Tumid Lupus Erythematosus (TLE): A Review of a Rare Variant of Chronic Cutaneous Lupus Erythematosus (cCLE) with Emphasis on Differential Diagnosis

Tumid Lupus Erythematosus (TLE): a review of a rare variant of chronic Cutaneous Lupus Erythematosus (cCLE) with emphasis on differential diagnosis

Contact Info

Product

Resources

About